View ValuationPharmagreen Biotech 将来の成長Future 基準チェック /06現在、 Pharmagreen Biotechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Dec 04Pharmagreen Biotech Inc. Files Form 15Pharmagreen Biotech Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common under the Securities Exchange Act of 1934, as amended.お知らせ • May 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/12/2023, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 09Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement ProductPharmagreen Biotech Inc., announced that it has completed development of its first formulated nutraceutical product and has commenced online sales via the Shopify ecommerce platform of its MaxGenomic™ Supplement. The company is also pleased to have entered the nutraceutical industry with this product development and be part of this multi-hundred-billion-dollar industry that is growing at a record pace. MaxGenomic™ Supplement comes in a bottle with 60 Enteric capsules (delayed release), for a one- or two-month supply, depending on suggested use. This all-natural product utilizes a combination of fifteen ingredients from medicinal plants and medicinal mushrooms. Pharmagreen’s proprietary blend is unique to the market, by combining mushrooms and herbs in one, delayed release, capsule. A nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to help and assist with repairing damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. Pharmagreen’s team focus is to help and aid, in the sales of MaxGenomic™ Supplement and additional nutraceutical products development. The company has plans to keep adding to the list of honorary sports ambassadors’ representatives. Pharmagreen’s near future plans also include launching additional products of its MaxGenomic™ brand designed for the extremely active, sports professionals and on the go individuals who are looking for immediate help and support before they begin and during their routine.お知らせ • Dec 29Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/28/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Sep 09Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product LaunchPharmagreen Biotech Inc. announced that it has developed its first formulated nutraceutical product and is in the process of organizing the retail sales distribution channels for its new product. The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms. Pharmagreen’s proprietary blend is unique to the market, a nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to repair damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. This product, and new products as they become available, can be purchased through the Company's soon to be launched online store, Shopify, Amazon and other third-party online outlets. Utilizing the Company's expertise in plant genetics and proprietary tissue culture technologies, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.お知らせ • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/14/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 17Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/16/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/14/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 18Pharmagreen Biotech Inc. Signs LOI to Supply Crude CBD Oil Extracted from Certified Organically Grown Hemp BiomassPharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of higher quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required. Pharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of highest quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required.お知らせ • Feb 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/12/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 30Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/29/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Pharmagreen Biotech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:PHBI - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20240000N/A9/30/20240-100N/A6/30/20240000N/A3/31/20240-100N/A12/31/20230-100N/A9/30/20230-100N/A6/30/20230-100N/A3/31/20230000N/A12/31/2022N/A-100N/A9/30/2022N/A-100N/A6/30/2022N/A-200N/A3/31/2022N/A-200N/A12/31/2021N/A-400N/A9/30/2021N/A-500N/A6/30/2021N/A-500N/A3/31/2021N/A-600N/A12/31/2020N/A-3-1-1N/A9/30/2020N/A-2-1-1N/A6/30/2020N/A-2-1-1N/A3/31/2020N/A0-10N/A12/31/2019N/A-100N/A9/30/2019N/A-1-10N/A6/30/2019N/A0-10N/A3/31/2019N/A-1-1-1N/A12/31/2018N/A-1-1-1N/A9/30/2018N/A-1N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PHBIの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PHBIの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PHBIの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PHBIの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PHBIの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PHBIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 01:34終値2026/05/22 00:00収益2024/12/31年間収益2024/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmagreen Biotech Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 04Pharmagreen Biotech Inc. Files Form 15Pharmagreen Biotech Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common under the Securities Exchange Act of 1934, as amended.
お知らせ • May 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/12/2023, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 09Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement ProductPharmagreen Biotech Inc., announced that it has completed development of its first formulated nutraceutical product and has commenced online sales via the Shopify ecommerce platform of its MaxGenomic™ Supplement. The company is also pleased to have entered the nutraceutical industry with this product development and be part of this multi-hundred-billion-dollar industry that is growing at a record pace. MaxGenomic™ Supplement comes in a bottle with 60 Enteric capsules (delayed release), for a one- or two-month supply, depending on suggested use. This all-natural product utilizes a combination of fifteen ingredients from medicinal plants and medicinal mushrooms. Pharmagreen’s proprietary blend is unique to the market, by combining mushrooms and herbs in one, delayed release, capsule. A nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to help and assist with repairing damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. Pharmagreen’s team focus is to help and aid, in the sales of MaxGenomic™ Supplement and additional nutraceutical products development. The company has plans to keep adding to the list of honorary sports ambassadors’ representatives. Pharmagreen’s near future plans also include launching additional products of its MaxGenomic™ brand designed for the extremely active, sports professionals and on the go individuals who are looking for immediate help and support before they begin and during their routine.
お知らせ • Dec 29Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/28/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 09Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product LaunchPharmagreen Biotech Inc. announced that it has developed its first formulated nutraceutical product and is in the process of organizing the retail sales distribution channels for its new product. The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms. Pharmagreen’s proprietary blend is unique to the market, a nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to repair damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. This product, and new products as they become available, can be purchased through the Company's soon to be launched online store, Shopify, Amazon and other third-party online outlets. Utilizing the Company's expertise in plant genetics and proprietary tissue culture technologies, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
お知らせ • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/14/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 17Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/16/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/14/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 18Pharmagreen Biotech Inc. Signs LOI to Supply Crude CBD Oil Extracted from Certified Organically Grown Hemp BiomassPharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of higher quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required. Pharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of highest quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required.
お知らせ • Feb 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/12/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 30Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/29/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.